Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

NANO-ENGINE

financed

Closed

A revolutionary cell programming platform based on the targeted nano-delivery of...

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system Aim: The NANO-ENGINE project aims to develop a first-in-class, DNA-based, non-viral, targeted in vivo cell programming technology that can be utilized for treating a broad range of diseases, including cancer and genetic disorders.... see more

31/03/2026

3M€

Project Budget: 3M€

Project leader

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 7 Participantes

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2023-03-15

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

725.24K€ | Leader

IMPERIAL COLLEGE OF SCIENCE...

N.D. | participant

SINTEF

548.97K€ | participant

NANOCELL THERAPEUTICS

1.14M€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 36 months Date Start: 2023-03-15
End date: 2026-03-31

Project leader

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 3M€

participation deadline Sin fecha límite de participación.

Project description Aim: The NANO-ENGINE project aims to develop a first-in-class, DNA-based, non-viral, targeted in vivo cell programming technology that can be utilized for treating a broad range of diseases, including cancer and genetic disorders. In this project, the consortium aims to assemble, characterize, and test the Targeted Nanoparticles, explore small-scale synthesis, conduct proof of concept studies and develop a preliminary business plan. Unmet need: Currently, the accessibility of cell therapies, specifically CAR-T cell therapy, to the general patient population is limited by high costs, complexity, and safety concerns. These limitations are caused by: 1) ex vivo manufacturing processes of adoptive cell technologies, 2) requirement of highly specialized clinical facilities, and 3) the clinical toxicities and the need for preconditioning chemotherapy. Therefore, there is a large unmet need for alternative approaches that makes adoptive cell therapy truly affordable, scalable, and widely accessible in an out-patient setting. Solution: We will develop Targeted Nanoparticles that form CAR-T cells in vivo, by combining a proprietary T cell binder-coated long-circulatory lipid nanoparticle and a non-viral, transposon-based, gene editing system. As such, we will circumvent the aforementioned issues associated with traditional cell therapies with reduced cost, complexity, and associated clinical risks, greatly increasing the accessibility of cell therapies to patients worldwide. Consortium: The consortium will leverage main applicant NANOCELL’s deep knowledge on non-viral gene transfer technologies. UU provides critical expertise on nanomedicine, protein and cell engineering. ICL has developed a revolutionary single particle analysis method, which allows the consortium to obtain unique drug product characterization insights. SINTEF adds crucial know-how on bulk analysis of Targeted Nanoparticles, and is closely involved in regulatory standards for nucleic acid therapeutics.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers